Amphastar Pharmaceuticals Inc AMPH
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AMPH is a good fit for your portfolio.
News
-
Amphastar Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
-
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
-
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2023
-
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023
-
Amphastar Pharmaceuticals Announces Pricing of Offering of $300.0 Million of Convertible Senior Notes
-
Amphastar Pharmaceuticals Shares Down 9% After Private Notes Offering
-
Amphastar Pharmaceuticals Announces Proposed Private Offering of $300.0 Million of Convertible Senior Notes
-
Eli Lilly to Sell Baqsimi Product to Amphastar
Trading Information
- Previous Close Price
- $58.22
- Day Range
- $58.13–59.94
- 52-Week Range
- $27.58–67.66
- Bid/Ask
- $56.72 / $59.90
- Market Cap
- $2.79 Bil
- Volume/Avg
- 395,764 / 471,290
Key Statistics
- Price/Earnings (Normalized)
- 18.49
- Price/Sales
- 5.10
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 2.73%
Company Profile
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,615
- Website
- http://www.amphastar.com
Valuation
|
Metric
|
AMPH
|
|---|---|
Price/Earnings (Normalized) | 18.49 |
Price/Book Value | 4.69 |
Price/Sales | 5.10 |
Price/Cash Flow | 16.48 |
Price/Earnings
AMPH
Financial Strength
|
Metric
|
AMPH
|
|---|---|
Quick Ratio | 1.63 |
Current Ratio | 2.10 |
Interest Coverage | 10.19 |
Quick Ratio
AMPH
Profitability
|
Metric
|
AMPH
|
|---|---|
Return on Assets (Normalized) | 16.11% |
Return on Equity (Normalized) | 30.08% |
Return on Invested Capital (Normalized) | 20.82% |
Return on Assets
AMPH
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
ZTS
| Zoetis Inc Class A | Bqw | $83.6 Bil | |
MKKGY
| Merck KGaA ADR | Pvtzts | $77.2 Bil | |
HLN
| Haleon PLC ADR | Pybx | $37.9 Bil | |
VTRS
| Viatris Inc | Kkb | $11.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Ckcqz | $11.4 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Tthf | $11.3 Bil | |
CTLT
| Catalent Inc | Rhxcvx | $6.8 Bil | |
PRGO
| Perrigo Co PLC | Ysz | $4.0 Bil | |
CURLF
| Curaleaf Holdings Inc | Jsq | $3.2 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Tkxcmz | $2.9 Bil |